Macleods Pharmaceuticals reminded a lot of blood pressure and heart medication Losartan for the presence of NDEA, and joined the many companies that recalled some Losartan, Valsartan or Irbesartan over the presumed carcinogen.
Although the impurity N-nitrosodiethylamine (NDEA) occurs naturally in many places, the International Agency for Cancer Research classifies it as a "probably carcinogenic to humans." But even the FDA stated in January that the actual increased risk of cancer by taking Losartan, Valsartan or Irbesartan with too much NDEA is small.
Register and save
Get six months of free digital access to the Miami Herald
Yet Macleods throws a lot of 100 mg / 25 mg Losartan tablet columns with potassium / hydrochlorothiazide in 90-count bottles with more NDEA than the acceptable daily intake levels of the FDA. It is batch number BLM715A with a shelf life of July 2019. The drug was manufactured in India.
The Macleods Recalling Message tells patients the same as the communications from other companies: until you receive alternative treatment with your doctor or pharmacist, continue using the Losartan. There is a greater risk of problems if you stop.
Anyone with questions can contact Qualanex, who processes the product returns for Macleods, by e-mail at firstname.lastname@example.org or by phone on 888-280-2042, 8 am to 5 pm & # 39; in the morning, Eastern time, from Monday to Friday.